Real-world assessment of sparsentan’s drug safety framework
Based on the available AE reporting data, sparsentan exhibits a favorable safety profile, with no high-priority clinical events identified. Our findings offer valuable insights to optimize the use of sparsentan and understand its potential side effects.
Authors
- Yuzhou Xue (ORCID: https://orcid.org/0009-0005-4212-7717)
- Dikang Pan (ORCID: https://orcid.org/0000-0001-8603-353X)
- Jingyu Wang (ORCID: https://orcid.org/0000-0003-1453-9587)
- Wenjing Fu
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Mianyang Central Hospital (CN)
- Peking University First Hospital (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2025-02-19
- DOI
- https://doi.org/10.1080/0886022x.2025.2461668
- Citations
- 6
- Primary Topic
- Complex Systems and Time Series Analysis
- Type
- article
- Field-Weighted Citation Impact
- 18.79
Funders
- National Natural Science Foundation of China